Steven R. Gullans Ph.D. is CEO & President at Gemphire Therapeutics Inc. (GEMP). They have made 6 open-market trades across 3 companies since 2013, most recently 2023-01-01.
CIK 0001638287
6 open-market purchases totalling $11.1M since 2013, never a sale. Across 6 scored buys the stock is up 1.9% at ninety days, and 0.2 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 50% | 33% |
| Avg Move | -8.4% | +8.7% | +1.9% |
| Alpha | -7.1% | +8.0% | +0.2% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GEMP | BUY | 2018-02-08 | 2018-02-12 | $7.00 | $500K | +4.1% | +13.0% | -10.6% |
| ALRN | BUY | 2017-07-05 | 2017-07-06 | $15.00 | $900K | -3.3% | -9.6% | +10.9% |
| GEMP | BUY | 2017-03-10 | 2017-03-14 | $9.47 | $1000K | +30.4% | +23.9% | +16.0% |
| GEMP | BUY | 2016-08-10 | 2016-08-12 | $10.00 | $5.0M | +4.7% | +26.3% | -3.3% |
| TTPH | BUY | 2014-05-19 | 2014-05-21 | $9.24 | $231K | -43.2% | -0.6% | -0.6% |
| TTPH | BUY | 2013-03-25 | 2013-03-27 | $7.00 | $3.5M | -43.2% | -0.6% | -0.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.